With the rapid acceleration of the spread of the COVID-19 virus in the United States in March 2020, telemedicine visits became more common for cancer care. However, in an evaluation of telemedicine inequities in 21 common cancers, there were distinctly lower levels of telemedicine use by Black patients and those who were uninsured, lived in suburban or rural areas, and resided in a neighborhood with low socioeconomic status. The research will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
A survey of metastatic breast cancer patients found that 83% of Black respondents were somewhat or very likely to consider clinical trial participation; however, 40% of those respondents reported that they had not been informed by their care team about the opportunity to enroll in a trial. The research will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
States that increased investments in social services spending by 10% compared to those that did not increase spending – including Medicaid and other social services for socioeconomically disadvantaged individuals – showed improved five-year overall survival for non-Hispanic Black adults with cancer, according to new research. There was also a decrease in racial disparities in survival between non-Hispanic Black and white patients for many different types of cancers. The study will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Children with high-risk neuroblastoma from historically marginalized racial and ethnic groups had a higher probability of dying than other children despite equal planned treatment on pediatric clinical trials, according to research that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Alexandria, Va — In an effort to highlight cancer care inequities during the COVID-19 pandemic, the American Society of Clinical Oncology (ASCO) has launched the Interactive Map of Oncology, a data visualization tool that allows users to explore geographic distribution of systemic and socioeconomic factors that influence cancer care delivery in the United States. Users can filter data on population demographics and risk factors by location overlaid with COVID-specific data from the COVID-19 in Oncology Registry (also known as the ASCO Registry) and other authoritative sources.
The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) today jointly released recommendations that address the lack of equity, diversity, and inclusion (EDI) in cancer clinical trials. Published in the Journal of Clinical Oncology, “Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement” details specific actions to engage the entire cancer clinical trial ecosystem in expanding the participation of underrepresented individuals in research that advances progress against cancer.
Oncology professionals from around the world will convene in Chicago to discuss the latest clinical cancer research impacting patient care at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Advances in therapies for rare and pediatric cancers, findings on disparities among patients with cancer, and new treatment options for patients with advanced breast, colorectal, and pancreatic cancers are among the topics that will be highlighted in the meeting’s official Press Program.
Alexandria, Va. – Today the American Society of Clinical Oncology (ASCO) announced six additional medical schools will participate in the second year of the Oncology Summer Internship (OSI) program, an immersive, four-week summer internship for rising second-year medical students from groups underrepresented in medicine (UIM).1 In 2022, ASCO and a total of 11 medical schools will lead approximately 50 students in a hybrid curriculum developed by members of ASCO’s OSI Advisory Group and each participating medical school’s internship leaders.
ASCO's CancerLinQ and Atropos Health announced on May 3 a collaboration that will provide oncology clinicians with the latest real-world evidence available to help inform personalized care and treatment of an individual patient.
The addition of tislelizumab to chemotherapy showed statistical and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy alone in patients with recurrent/metastatic nasopharyngeal cancer. These findings will be presented during the ASCO Plenary Series session taking place April 19, 2022, at 3:00 p.m. ET.
The American Society of Clinical Oncology (ASCO) today announced the establishment of the ASCO Center for Equity, Diversity, and Inclusion, which will advance the Society’s equity, diversity, and inclusion (EDI) goals across the organization and throughout the wider oncology community. ASCO Chief Equity, Diversity and Inclusion Officer Sybil Green will serve as the Center’s inaugural vice president with lead responsibility for guiding and organizing the organization’s far-reaching external and internal EDI efforts.
The Association for Clinical Oncology (ASCO) today presented Representatives Diana DeGette (D-CO-1) and Fred Upton (R-MI-6) with the annual Congressional Champion for Cancer Care Award in recognition of their commitment to legislation that focuses on medical innovation. The award honors Members of Congress who are leading champions for patients and survivors of cancer, their families, and their care delivery teams.
The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Edward Balaban, DO, FACP, FASCO for his valuable contributions to ASCO’s advocacy efforts. The award recognizes volunteers who have gone above and beyond in the past year, advocating on behalf of patients and providers to improve cancer care and research.
Boston and Alexandria, VA – ASCO’s CancerLinQ® and Count Me In announced today a new collaboration that aims to allow cancer researchers to learn from every patient with cancer, by actively engaging patients as part of the clinical research enterprise. CancerLinQ – a real world oncology data technology platform developed by the American Society of Clinical Oncology (ASCO) – collects and aggregates de-identified EHR data from oncology practices across the United States to advance cancer care through quality improvement and research. Count Me In, a non-profit research initiative of the Broad Institute of MIT and Harvard, the Emerson Collective, and Dana-Farber Cancer Institute, provides patients with a mechanism to participate in cancer research by sharing their unique, de-identified medical information and history with cancer researchers and investigators.
The Association for Clinical Oncology (ASCO) congratulates Dr. Norman E. “Ned” Sharpless on his successful tenure as Director of the National Cancer Institute (NCI). During his five years at NCI, Dr. Sharpless guided the Institute to advance the goals of the Cancer Moonshot Initiative, including important work to modernize cancer clinical trials to reflect an improved understanding of biology and the new types of therapies available to treat cancer. We are hopeful that these efforts will endure even after Dr. Sharpless’ departure later this month.